Lonza’s Synaffix platform entered a licensing agreement with South Korea’s Qurient Therapeutics to develop a clinical-stage dual-payload antibody-drug conjugate (ADC) targeting solid tumors. The ADC combines Synaffix’s exatecan-based linker-payload and Qurient’s CDK7 inhibitor, aiming to overcome cancer resistance while minimizing off-target toxicity. The collaboration includes access to advanced antibody conjugation technologies and manufacturing services from Lonza and R&D plus commercialization efforts from Qurient. Dual-payload ADCs represent an emerging frontier in oncology offering synergistic mechanisms against tumors.